Class Action Cases

Karyopharm Therapeutics Inc.

Join Class Action »

According to the Complaint, the Company made false and misleading statements to the market. Karyopharm repeatedly hyped the commercial prospects of its drug selinexor. The Company focused on the safety and efficacy of the drug, describing it as having a  “predictable and manageable tolerability profile,” adding that it had a “very nice safety profile,” and was “well tolerated” by patients. In reality, the FDA found that “[t]reatment with selinexor is associated with significant toxicity” and has “limited efficacy.” Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Karyopharm, investors suffered damages.

Press Release

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, July 25, 2019 — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between March 2, 2017 and February 22, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 23, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Karyopharm repeatedly hyped the commercial prospects of its drug selinexor. The Company focused on the safety and efficacy of the drug, describing it as having a “predictable and manageable tolerability profile,” adding that it had a “very nice safety profile,” and was “well tolerated” by patients. In reality, the FDA found that “[t]reatment with selinexor is associated with significant toxicity” and has “limited efficacy.” Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Karyopharm, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE:
The Schall Law Firm